Showing results (21-30 of 92) with videos related to

Sort By:
Pageof 10
Journal of Clinical Medicine|May 25, 2024
Rationale for the Potential Use of Recombinant Activated Factor VII in Severe Post-Partum HemorrhageNándor Ács, Wolfgang C Korte, Christian C von Heymann, et al.
The Cochrane Database of Systematic Reviews|April 30, 2015
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgeryAntonio Coppola, Jerzy Windyga, Antonella Tufano, et al.
Therapeutic Advances in Hematology|July 18, 2018
BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product reviewJohnny N Mahlangu, Sanjay P Ahuja, Jerzy Windyga, et al.
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego|December 17, 2009
[Strategy for secure hemostasis in hemophilia patients undergoing surgery for malignant neoplasms]Andrzej B Szczepanik, Sławomir Wisławski, Jerzy Windyga, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 8, 2008
The first case of combined coagulation factor V and coagulation factor VIII deficiency in Poland due to a novel p.Tyr135Asn missense mutation in the MCFD2 geneVytautas Ivaskevicius, Jerzy Windyga, Beata Baran, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 27, 2021
Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgeryIngrid Pabinger, Vasily Mamonov, Jerzy Windyga, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 1, 2020
Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation StudyJerzy Windyga, Oleksandra Stasyshyn, Toshko Lissitchkov, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 17, 2025
Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With InhibitorsManuel Carcao, Cédric Hermans, Adam Giermasz, et al.
Polskie Archiwum Medycyny Wewnetrznej|August 22, 2009
Therapeutic properties and safety of recombinant factor VIII and factor IXJoanna Zdziarska, Krzysztof Chojnowski, Anna Klukowska, et al.
Expert Review of Hematology|August 9, 2021
Addressing unmet needs in rare bleeding disorders: selected poster extracts of recent research in hemophilia A and von Willebrand disease presented at the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (Feb 3-5, 2021; virtual congress)Geoffrey Allen, Ping Du, Kate Khair, et al.
Pageof 10